Royalty Pharma plc (NASDAQ:RPRX) shares traded 2.20% higher at $30.21 on Wall Street last session.
In accordance with the data, 8 analysts cover Royalty Pharma plc (NASDAQ:RPRX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $60.00 and a low of $40.00, we find $48.90. Given the previous closing price of $29.56, this indicates a potential upside of 65.43 percent. RPRX stock price is now -1.33% away from the 50-day moving average and -15.49% away from the 200-day moving average. The market capitalization of the company currently stands at $17.79B.
It has been rated a hold by 0 analysts and a buy by 8. Brokers who have rated the stock have averaged $48.35 as their price target over the next twelve months.
In other news, Coyne Terrance P., EVP & CFO sold 37,500 shares of the company’s stock on Aug 10. The stock was sold for $1,153,091 at an average price of $30.75. Upon completion of the transaction, the EVP & CFO now directly owns 790,000 shares in the company, valued at $23.87 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 09, EVP & CFO Coyne Terrance P. sold 37,500 shares of the business’s stock. A total of $1,151,936 was realized by selling the stock at an average price of $30.72. This leaves the insider owning 827,500 shares of the company worth $25.0 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RPRX stock. A new stake in Royalty Pharma plc shares was purchased by WS PORTFOLIO ADVISORY, LLC during the first quarter worth $16,432,000. JUMP FINANCIAL, LLC invested $13,784,000 in shares of RPRX during the first quarter. In the first quarter, TWINBEECH CAPITAL LP acquired a new stake in Royalty Pharma plc valued at approximately $12,377,000. HRT FINANCIAL LP acquired a new stake in RPRX for approximately $10,958,000. UNISUPER MANAGEMENT PTY LTD purchased a new stake in RPRX valued at around $6,653,000 in the second quarter. In total, there are 561 active investors with 68.40% ownership of the company’s stock.
Royalty Pharma plc (NASDAQ: RPRX) opened at $29.55 on Friday. During the past 12 months, Royalty Pharma plc has had a low of $28.98 and a high of $44.47. As of last week, the company has a debt-to-equity ratio of 1.13, a current ratio of 2.50, and a quick ratio of 2.50. According to the stock market information, the enterprise value for the company is $17.78B, which is based on a 53.75 price-to-earnings ratio, a 10.86 price-to-earnings-growth ratio, and a beta of 0.40. The fifty day moving average price for RPRX is $30.58 and a two-hundred day moving average price translates $35.68 for the stock.
The latest earnings results from Royalty Pharma plc (NASDAQ: RPRX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.84, beating analysts’ expectations of $0.81 by 0.03. This compares to $0.81 EPS in the same period last year. The net profit margin was 10.80% and return on equity was 4.20% for RPRX. The company reported revenue of $538.2 million for the quarter, compared to $535.96 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.42 percent. For the current quarter, analysts expect RPRX to generate $615.99M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/15/2023. Investors who held shares on 08/18/2023 were paid a $0.20 dividend. On an annualized basis, this represents a $0.80 dividend and a 2.65% percent yield. There was an ex-dividend date of 08/17/2023 for this dividend. In terms of dividend payout ratio, RPRX is presently at 138.40%.
Royalty Pharma plc(RPRX) Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
